Vasoactive Intestinal Polypeptide is measured by a direct ELISA.
VIP
EDTA Plasma
Patient Preparation: The patient should fast for 10 to 12 hours prior to collection of specimen. Patient should not be on any antacid medications or medications that affect intestinal motility for at least 48 hours prior to collection.
Specimen Type: Plasma
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Preservative-free plastic vial
Specimen Volume: 1 mL
Collection Instructions: Draw blood in an EDTA (lavender top) tube(s). Spin down and freeze immediately. Send 1 mL of plasma frozen in a preservative-free plastic vial.
0.5 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
EDTA Plasma | Frozen | 180 days |
Vasoactive Intestinal Polypeptide (VIP) is a 28 amino acid multifunctional peptide that is involved in gastrointestinal, vasodilator, and neuroendocrine functions. VIP is derived from larger pro-molecules that often exhibit the same or greater immunogenicity than the native VIP. It is structurally related to PHIM, Glucagon, Secretin, Gastric Inhibitory Polypeptide, Corticotropin Releasing Factor and Growth Hormone-Releasing Hormone. VIP stimulates pituitary release of Prolactin, Growth Hormone and ACTH; stimulates Luteinizing Hormone-Releasing Hormone, Serotonin, gastric Somatostatin, Steroids and Renin. VIP inhibits the release of Gastrin, hypothalamic Somatostatin, and Histamine. VIP release is stimulated by cholinergic agonists, Atropine, Serotonin, Prostaglandins E1 and D2, and Nerve Growth Factor. VIP actions are inhibited by Corticosteroids, Dopamine and opiate agonists. Elevated levels of VIP are found in patients with VIPomas, hepatic cirrhosis, and the Verner-Morrison’s (Watery Diarrhea) Syndrome. Decreased levels are found in cystic fibrosis.
Up to 36 pg/mL
(mean 14)
1. MS O’Dorisio, CL Wood, and TM O’Dorisio. Vasoactive Intestinal Peptide and Neuropeptide Modulation of the Immune Response. Journal of Immunology 135: 792, 1985.
2. S Ollerenshaw, D Jarvis, A Woolcock. Absence of Immunoreactive Vasoactive Intestinal Polypeptide in Tissue from the Lungs of Patients with Asthma. New England Journal of Medicine 320: 1244, 1989
Monday through Friday
This test was developed and its performance characteristics determined by Inter Science Institute. It has not been cleared or approved by the US Food and Drug Administration. The FDA had determined that such clearance or approval is not necessary.
84586
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
FVIP2 | VIP, Plasma | 3125-2 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
FVIP2 | VIP, Plasma | 3125-2 |